Product Information Sheet for NR-51195

H7 Hemagglutinin (HA) Protein from Influenza Virus, A/Hunan/02285/2017 (H7N9), Recombinant from Baculovirus

Catalog No. NR-51195

This reagent is the tangible property of the U.S. Government.

For research use only. Not for human use.

Contributor:

Florian Krammer, Ph.D., Departments of Medicine and Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levey Place, New York, New York, USA, provided under government contract (CEIRS)

Manufacturer:

BEI Resources

Product Description:

A recombinant form of the H7 hemagglutinin (HA) protein from influenza A virus, A/Hunan/02285/2017 (H7N9) was produced in Sf9 insect cells using a baculovirus expression system and purified by immobilized metal-affinity chromatography.[1-3] The recombinant HA protein consists of the HA ectodomain, thrombin cleavage site, T4 foldon trimerization domain and a hexahistidine tag.[1,2]

Material Provided:

Each vial contains approximately 0.5 mL of purified recombinant HA protein in phosphate buffered saline (pH 7.4) and 50% glycerol. The concentration, expressed as µg per mL, is shown on the Certificate of Analysis.

Packaging/Storage:

Purified recombinant HA protein was packaged aseptically, in screw-capped plastic cryovials. This product is provided on blue ice and should be stored at -20°C immediately upon arrival.

Functional Activity:

NR-51195 is functional in SDS-PAGE, western blot and ELISA.[1,3]

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: H7 Hemagglutinin (HA) Protein from Influenza Virus, A/Hunan/02285/2017 (H7N9), Recombinant from Baculovirus, NR-51195."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Krammer, F., et al., Personal Communication.
2. Margine, I., P. Palese and F. Krammer. "Expression of Functional Recombinant Hemagglutinin and Neuraminidase Proteins from the Novel H7N9 Influenza Virus Using the Baculovirus Expression System." J. Vis. Exp. 6 (2013): e51112. PubMed: 24300384.
3. Stadlbauer, D., et al. "Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans." mSphere 2 (2017): e00502-17. PubMed: 29242836.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898